Key Takeaways
- • IGIS Asia Investment Management and CHA Bio Group have formed a joint venture to develop and invest in life science real estate across the Asia-Pacific region, targeting R&D facilities, manufacturing plants, hospitals, and medical offices.
- • The platform addresses a structural market opportunity: APAC life sciences real estate investment represented only 1% ($717 million USD) of total real estate investment in 2022, despite growing investment demand that has raised $18 billion in dedicated life sciences real estate funds over the past five years.
- • The venture will establish the Korea Life Science Investment Platform as an initial focus, reflecting South Korea's growing importance as a life sciences hub in the region.
- • The joint venture targets best-in-class life science real estate across multiple asset classes, including greenfield development, brownfield repositioning, and repositioning strategies aligned with the sector's structural realignment across Asia-Pacific.
Summary
IGIS Asia Investment Management Partners and CHA Bio Group have launched a joint venture focused exclusively on life science real estate investment and development across the Asia-Pacific region. The platform will develop and deploy capital across a diversified portfolio of life sciences assets, including research and development facilities, manufacturing plants, hospitals, and medical offices, positioning itself to capture growth in a materially underinvested segment of regional real estate markets.
The venture addresses a significant market inefficiency. As of 2022, life sciences real estate investment in APAC represented only 1% ($717 million USD) of total real estate investment in the region, despite robust capital formation activity in the sector. Over the past five years, investment funds have raised $18 billion specifically for life sciences real estate deployment, signaling institutional appetite for exposure to this asset class. This capital-to-opportunity gap suggests the region's life sciences ecosystem is underserved by dedicated real estate solutions.
The partnership will initially focus on establishing the Korea Life Science Investment Platform, reflecting South Korea's strategic importance within APAC's life sciences landscape. The broader venture targets best-in-class real estate solutions across multiple development strategies, including greenfield development, brownfield repositioning, and repositioning of existing assets. This strategic approach reflects the structural realignment underway in Asia-Pacific's life sciences sector, which is driving fundamental shifts in market dynamics and portfolio expansion requirements for institutional investors.
The formation of this platform aligns with a broader institutional trend toward sector-specific real estate investment vehicles in APAC, where life sciences remains an underpenetrated asset class relative to capital availability and sector growth fundamentals.
The venture addresses a significant market inefficiency. As of 2022, life sciences real estate investment in APAC represented only 1% ($717 million USD) of total real estate investment in the region, despite robust capital formation activity in the sector. Over the past five years, investment funds have raised $18 billion specifically for life sciences real estate deployment, signaling institutional appetite for exposure to this asset class. This capital-to-opportunity gap suggests the region's life sciences ecosystem is underserved by dedicated real estate solutions.
The partnership will initially focus on establishing the Korea Life Science Investment Platform, reflecting South Korea's strategic importance within APAC's life sciences landscape. The broader venture targets best-in-class real estate solutions across multiple development strategies, including greenfield development, brownfield repositioning, and repositioning of existing assets. This strategic approach reflects the structural realignment underway in Asia-Pacific's life sciences sector, which is driving fundamental shifts in market dynamics and portfolio expansion requirements for institutional investors.
The formation of this platform aligns with a broader institutional trend toward sector-specific real estate investment vehicles in APAC, where life sciences remains an underpenetrated asset class relative to capital availability and sector growth fundamentals.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.